Belzupacap Sarotalocan · AU-011

What is Belzupacap Sarotalocan?

Belzupacap sarotalocan is a formulation of human papillomavirus-derived nanoparticles conjugated to the near-infrared photosensitizer IR700. The nanoparticles bind heparan sulfate proteoglycans overexpressed on ocular melanoma cells, and after near-infrared light activation IR700 generates reactive oxygen species that damage the melanoma cell membrane. It is being studied in uveal and choroidal melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

AU-011, Bel-sar, Light-activated AU-011

Drug type

Small molecule

Targets

heparan sulfate proteoglycans (HSPG)

Mechanism

Kills target cells, directed at heparan sulfate proteoglycans (HSPG)

Pathways

reactive oxygen species generation, melanoma cell membrane damage and necrosis

Therapy area

Oncology

Developer

Aura Biosciences (AURA)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

DK0ZGA5Y2R

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Eye CancerIndeterminate LesionsPrimary CancerChoroidal MelanomaOcular MelanomaUveal Melanoma

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT06007690
• ClinicalTrials.gov NCT06643884

Updated Oct 11, 2026. Something wrong or missing? Report it on the AURA page.